stockrow
Friday 6 November 2026
Export AUPH’s income statement to Excel — free account
Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
16.48
0.27
+1.67%
Follow AUPH
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
6.78 | 7.10 | 6.56 | 7.35 |
+8 more quarters Free account |
P/S ratio |
6.72 | 7.09 | 6.58 | 7.57 | |
P/FCF ratio |
12.21 | 12.61 | 11.77 | 15.83 | |
P/Operating CF |
46.62 | 41.99 | 60.25 | 46.93 | |
P/B ratio |
3.29 | 3.59 | 3.46 | 3.69 | |
Price to Tangible BV |
3.30 | 3.61 | 3.48 | 3.71 | |
EV/Sales |
5.33 | 5.81 | 5.47 | 6.35 | |
EV/EBITDA |
10.49 | 11.30 | 10.93 | 13.42 | |
EV/Operating CF |
9.67 | 10.32 | 9.77 | 13.25 | |
EV/FCF |
9.68 | 10.33 | 9.79 | 13.27 | |
Quick Ratio |
5.57 | 4.85 | 4.94 | 4.69 | |
Current Ratio |
6.12 | 5.42 | 5.55 | 5.25 | |
Net Debt/EBITDA |
(11.50) | (8.88) | (7.11) | (10.47) | |
Debt/Assets |
4.73% | 5.55% | 6.65% | 6.96% | |
Debt/Equity |
0.06 | 0.07 | 0.08 | 0.09 | |
Asset Turnover |
0.48 | 0.48 | 0.49 | 0.43 | |
Operating CF/Net income |
1.46 | 1.41 | 0.95 | 0.22 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.01) | |
Interest Coverage |
39.33 | 42.31 | 41.21 | 26.90 | |
Research and Development Expense of Revenue |
19.85% | 15.68% | 9.61% | 14.13% | |
Selling, General and Administrative Expense of Revenue |
29.49% | 28.25% | 28.35% | 37.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
7.32% | 3.41% | (1.11%) | 8.72% | |
Graham Net Nets |
0.19 | 0.16 | 0.17 | 0.15 | |
Graham Number |
16.28 | 15.94 | 14.77 | 14.53 | |
Earnings Yield |
14.75% | 14.08% | 15.25% | 13.61% | |
Free Cash Flow Yield |
8.19% | 7.93% | 8.49% | 6.32% | |
Revenue per Share |
0.63 | 0.64 | 0.59 | 0.57 | |
Operating CF per Share |
0.35 | 0.40 | 0.25 | 0.34 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.35 | 0.40 | 0.25 | 0.34 | |
Cash per Share |
3.65 | 3.41 | 2.86 | 2.96 | |
Shareholders Equity per Share |
4.93 | 4.73 | 4.29 | 4.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.93 | 4.73 | 4.29 | 4.33 | |
Free Cash Flow |
46.34 | 52.57 | 32.52 | 45.60 | |
Working Capital |
491.88 | 441.43 | 393.69 | 398.24 | |
Capital Expenditures |
(0.02) | 0.00 | (0.04) | (0.07) | |
Net Current Asset Value |
419.70 | 363.93 | 323.87 | 321.71 | |
EV/EBIT |
11.90 | 12.86 | 12.56 | 15.71 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
15.00 | 15.70 | 15.11 | 18.73 | |
| Other line items | |||||
Average Receivables |
39.07 | 40.61 | 44.76 | 39.00 | |
Average Payables |
2.61 | 2.52 | 3.44 | 4.25 | |
Average Inventory |
44.26 | 45.83 | 46.30 | 42.46 | |
Average Assets |
676.62 | 647.41 | 614.42 | 651.12 | |
Average Common Equity |
511.65 | 475.08 | 458.91 | 479.40 |
Columns are period end dates · fundamentals updated 5 Nov 2026